These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36721765)

  • 1. Economic Burden of HIV in a Commercially Insured Population in the United States.
    Chen CY; Donga P; Campbell AK; Taiwo B
    J Health Econ Outcomes Res; 2023; 10(1):10-19. PubMed ID: 36721765
    [No Abstract]   [Full Text] [Related]  

  • 2. Pre-exposure prophylaxis for preventing acquisition of HIV: A cross-sectional study of patients, prescribers, uptake, and spending in the United States, 2015-2016.
    Chan SS; Chappel AR; Maddox KEJ; Hoover KW; Huang YA; Zhu W; Cohen SM; Klein PW; De Lew N
    PLoS Med; 2020 Apr; 17(4):e1003072. PubMed ID: 32275654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
    Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO
    J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883
    [No Abstract]   [Full Text] [Related]  

  • 4. Healthcare resource utilization and costs in individuals with Huntington's disease by disease stage in a US population.
    Exuzides A; To TM; Abbass IM; Ta JT; Patel AM; Surinach A; Fuller RLM; Luo J
    J Med Econ; 2022; 25(1):722-729. PubMed ID: 35608039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A retrospective US claims database analysis.
    Yang J; Boytsov N; Carlson JJ; Barthold D
    J Manag Care Spec Pharm; 2023 Aug; 29(8):917-926. PubMed ID: 37523320
    [No Abstract]   [Full Text] [Related]  

  • 6. Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia.
    Fu AZ; Pesa JA; Lakey S; Benson C
    BMC Psychiatry; 2022 Apr; 22(1):250. PubMed ID: 35395757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States.
    Jain SS; Li SS; Xie J; Sutton MB; Fine JT; Edelberg JM; Gao W; Spertus JA; Cohen DJ
    J Med Econ; 2021; 24(1):1115-1123. PubMed ID: 34493144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newly Diagnosed Hepatitis C in the US Commercially Insured Population Before and After the 2012 Implementation of Expanded Screening Guidelines.
    Pyenson BS; Dieguez G; Ferro C; Mavinkurve M; Gonzalez YS
    Am Health Drug Benefits; 2018 Feb; 11(1):30-37. PubMed ID: 29692878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States.
    Atallah EL; Maegawa R; Latremouille-Viau D; Rossi C; Guérin A; Wu EQ; Patwardhan P
    J Health Econ Outcomes Res; 2022; 9(2):19-29. PubMed ID: 35979528
    [No Abstract]   [Full Text] [Related]  

  • 10. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
    Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
    J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic burden to commercial payers of young adults with schizophrenia in Colorado.
    Pesa J; Patel C; Rotter D; Papademetriou E; Potluri R; Benson C
    J Med Econ; 2021; 24(1):1194-1203. PubMed ID: 34666605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Productivity loss outcomes and costs among patients with cholangiocarcinoma in the United States: an economic evaluation.
    Parasuraman S; Thiel E; Park J; Teschemaker A
    J Med Econ; 2023; 26(1):454-462. PubMed ID: 36883994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Pain Severity and Opioid Use on Health Care Resource Utilization and Costs Among Patients with Knee and Hip Osteoarthritis.
    Wei W; Gandhi K; Blauer-Peterson C; Johnson J
    J Manag Care Spec Pharm; 2019 Sep; 25(9):957-965. PubMed ID: 31456495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
    Asche CV; Singer ME; Jhaveri M; Chung H; Miller A
    J Manag Care Pharm; 2010; 16(9):703-12. PubMed ID: 21067256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.
    Kearney M; Thokagevistk K; Boutmy E; Bharmal M
    J Med Econ; 2018 Dec; 21(12):1159-1171. PubMed ID: 30149739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence With Human Immunodeficiency Virus Pre-exposure Prophylaxis in the United States, 2012-2017.
    Huang YA; Tao G; Smith DK; Hoover KW
    Clin Infect Dis; 2021 Feb; 72(3):379-385. PubMed ID: 33527117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare resource utilization and cost among individuals with late-onset versus adult-onset Huntington's disease: a claims‑based retrospective cohort study.
    To TM; Ta JT; Patel AM; Arndorfer S; Abbass IM; Gandhy R
    J Med Econ; 2023; 26(1):862-870. PubMed ID: 37350423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health Care Utilization and Economic Burden in Patients with Central Precocious Puberty: An Assessment of the Commercially Insured and Medicaid Populations.
    Klein K; Soliman AM; Bonafede M; Nelson JK; Grubb E
    J Manag Care Spec Pharm; 2019 Jul; 25(7):836-846. PubMed ID: 31232203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral Treatment Switching and Its Association With Economic Outcomes and Adverse Treatment Effects Among Commercially Insured and Medicaid-Enrolled Patients With HIV in the United States.
    Korsnes JS; Goodwin BB; Murray M; Candrilli SD
    Ann Pharmacother; 2016 Dec; 50(12):989-1000. PubMed ID: 27439947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.